OBT and Boehringer Ingelheim Enter Collaboration
News Apr 29, 2013
Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) have announced a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.
Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications.
Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.
OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.
Christian Rohlff, CEO of OBT, commented: “Selecting the right target is fundamental for the successful development of a first-in-class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development.”
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE